Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

HTA Data

HTA Data

NAVLIN HTA provides real-time updates across 40+ bodies, including detailed information on benefits assessments and economic evaluations. Data include economic modeling results, clinical trial evidence, and economic and clinical drivers. In addition, pricing, regulatory data, epidemiology, and managed entry agreements are included in one place.

Easily compare decisions across products and their comparators at the indication level with the most comprehensive HTA coverage.

Tender Data

Tender Data

The NAVLIN Tender data tool tracks tenders in 40+ countries from 100+ sources behind TED. Tender award prices, including vaccine prices, are captured where publicly available and opportunities are displayed in easily readable calendar format.

Improve strategic decision-making process with global analytics and insights to local dynamics in real time.

Cost of Treatment Data

Cost of Treatment Data

The Cost of Treatment module allows users to view treatment outputs without any effort by utilizing the list price, and pre-populated dosing assumptions.

NAVLIN Price & Access Data’s cost of treatment data is available at indication level across all therapeutic areas.

Reimbursement Data

Reimbursement Data

Easy access to HTA Decisions and Reimbursement decisions from within the Pricing and HTA database.

NAVLIN Price & Access Data includes standardized reimbursement decision details at the indication level for maximum accuracy.

Analogue ID

Analogue ID

NAVLIN Analogue ID offers the most comprehensive set of analogue data, along with a customizable, proprietary search algorithm, to guide to answer your most challenging analogue questions. Deliver comprehensive and accurate pricing analyses, quickly and confidently.

Spend less time searching and more time building your strategy with our custom analogue identification process, based on over 100 possible attributes.

News & Country Reports

News & Country Reports

The NAVLIN Price & Access Data news and country reports include over 80 global markets covering country specific coverage of healthcare systems, pricing & reimbursement processes and risks and trends in the market.

Get daily policy and reimbursement updates for products around the globe.

Brand Access

Brand Access

NAVLIN Insights’ Brand Access identifies current and future opportunities to optimize access for your brands.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

EPA CONGRESS 2023: Experts Voice "Concerns" over EU…

Speaking at the EPA World conference 2023 in Amsterdam, EUCOPE’s secretary general, Alexander Natz called for constructive dialogue to address the issues identified in the upcoming joint EU health technology assessment (HTA), such as the duplication of work “The devil is in the detail,” Natz added, referring to the final text agreed between Member States, which he believes does not allow for a full binding effect on Joint Clinical Assessment (JCA) reports Echoing Natz, AbbVie’s Greek Market Access & External Relations Director, Penny Retsa, stated: “EU member states need to work together in order to reach an alignment because even though I am very optimistic as a person, there are a lot of concerns within the process at the moment” 

NICE Backs Zolgensma for Presymptomatic Babies with…

The National Institute for Health and Care Excellence (NICE) has published a draft guidance recommending Novartis’ Zolgensma (onasemnogene abeparvovec) as an option in babies with presymptomatic 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and up to three copies of the SMN2 geneThe list price for Zolgensma is £1,795,000 (excluding VAT), but the company has a commercial arrangement in place making the gene therapy available to the NHS at a confidential discountThe recommendation means that Zolgensma will be the first treatment to be routinely commissioned for presymptomatic babies with SMA in England, which will help them have the best chance for optimal outcomes

PhRMA Proposes FY2024 Japan Drug Pricing Reform

On March 9, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced new policy proposals for Japan’s FY2024 drug pricing reformSpeaking at a press conference in Tokyo, Simone Thomsen, chair of PhRMA’s Japan-based Executive Committee, called FY2024 a “turning point,” as in recent years several important drugs have not been launched in Japan due to “drug lag”At the meeting, she laid out some priorities for the FY2024 drug pricing reform to prevent the drug lag from worsening, such as a review of actual market price-based revisions, improvement of market expansion repricing rules and amendments to the initial price-setting rules

NICE Proportionate Approach Could be 45% Faster

Last year, the National Institute for Health and Care Excellence (NICE) underscored its ongoing efforts to place the UK as a “world leader in medicines evaluation” by announcing its intention to take a “proportionate approach” to technology appraisals - Ultimately, NICE hopes to increase its capacity by 20% by April 2023, to keep up with clinical practices. To achieve this, the organization is currently “piloting ideas for real appraisals and learning from the real world,” which results in a simultaneous capacity benefit and provides guidance and accessSpeaking at a recent webinar, “A proportionate approach to technology appraisals - pilot learnings and next steps,” on Thursday, 9 March, Jenna Dilkes, Associate Director of Planning & Operations, Technology Appraisals & HST at NICE outlined some of the concepts and principles underlining the initiative, while other NICE members highlighted ongoing initiatives to achieve the aimsNICE is currently running pilots to help inform what a light-touch approach might be for appropriate treatments. These include a novel approach to entry for managed access, pathway appraisals, the use of pre-specified assumptions and pair appraisals

DAK-Gesundheit Report Predicts Impact of Financial…

DAK-Gesundheit (DAK), together with the University of Bielefeld and VANDAGE, has carried out a structured analysis of the financial effects of the measures contained in the “Financial Stabilization of the Statutory Health Insurance System” (GKV-Finanzstabilisierungsgesetz) billThe report analyses potential outcomes from the new orphan drug threshold, the reduced free pricing, combination discounts and the amended AMNOG rebate negotiation guardrailsBased on its analysis, DAK sees that three quarters of the newly registered active substances considered from the last three years - up to 2021 - would be affected by a restriction by the guardrails after their initial assessment. The average discount that would result from the specifications for the 70 active substances considered with a quantifiable guardrail discount was found to be 44.4% and thus more than 50% above the average reimbursement discount after the initial assessment

Minnesota Lawmakers Advance Bill to Establish…

Democratic lawmakers have advanced a bill to tackle prescription drug prices through the Minnesota House of RepresentativesThe bill would establish a Prescription Drug Affordability Board with the authority to set upper limits for certain high-cost drugs, as well as prohibit manufacturers from imposing or causing to be imposed an excessive price increase on the sale of any generic or off-patent drugHF 17 and its companion bill, SF 168, have garnered considerable pushback from the pharmaceutical industry

BMS Will Not Launch Opdualag in Germany, Cites G-BA…

Bristol Myers Squibb has revealed that it plans not to launch Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1% “for the foreseeable future”According to the company, it sees “no possibility of achieving a benefit assessment for Opdualag that would reflect the value of this medical innovation compared with the comparator therapy,” as the Federal Joint Committee (G-BA) does not accept progression-free survival (PFS) as a patient-relevant endpointAccording to media reports, BMS said that it is “disappointed that this is not possible in Germany at this time due to the current benefit assessment system and recent GKV-FinStG reforms,” however, it remains open to reconsidering should that change in the future

Novo Plans UK Launch of Wegovy Following NICE…

According to the National Institute for Health and Care Excellence (NICE), Novo Nordisk is planning to launch Wegovy (semaglutide) “soon” following a final positive recommendationA newly released appraisal consultation document backs the drug for the treatment of adults with at least one weight-related condition and a body mass index (BMI) of at least 35 kg/m2, and exceptionally, to people with a BMI of 30.0 kg/m2 to 34.9 kg/m2The decision is based on results of the STEP clinical trial, which involved more than 1,500 people who were treated with the drug over a 68-week period – the trial showed that people who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo, which is considered to be a clinically important result. However, following the endorsement, Helen Knight, director of medicines evaluation at NICE, said that Wegovy “won’t be available to everyone,” as the committee has “made specific recommendations to ensure it remains value for money for the taxpayer, and it can only be used for a maximum of two years”

France Expands Early Access Scheme for Yescarta

France’s High Health Authority (HAS) has expanded the post-marketing authorization (MA) early access scheme for Yescarta (axicabtagene ciloleucel) to include patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who have relapsed within 12 months after the end of the first line of chemo-immunotherapy, or who are refractory to itThe early access request is based on the phase III ZUMA-7 study, in which comparative versus salvage chemotherapy followed in the event of an intensification response and an HSC autograft in patients with refractory DLBCL or patients in relapse within 12 months after a first line of treatment and eligible for intensification chemotherapy with a view to an autograft of CSHFollowing the Transparency Commission’s (CT) decision to initiate the early access scheme, the initiative is set for a period of 12 months from the notification of the decision, but the ultimate decision to authorize early access or not rests with the HAS Board

MHLW Publishes List Prices for 2023 Off-year Repricing

Japan’s Ministry of Health, Labor and Welfare (MHLW) has announced the new national health insurance (NHI) prices to be applied through the FY2023 “off-year” drug price revisionPublished in the official gazette on March 3, the revision targets items exceeding 0.625 times the average discrepancy rate of 7% and includes special raises for the price maintenance premium (PMP) to be applied to 143 products. The revisions will be implemented on April 1, 2023According to a document released by the MHLW, the repricing efforts will cover 18,197 listed products, including 11,875 oral drugs, 3,871 injectables, 2,425 topical agents, and 26 dental medicines

Contact Us

Connect With Our Team Of Global Experts

Feel free to get in touch with us via email, live chat, or schedule a meeting!